63744-22-9

Usage

Uses

Used in Pharmaceutical Industry:
6,8-Dibromoimidazo[1,2-a]pyrazine is used as a pharmaceutical compound for its uterine-relaxing, antibronchospastic, and cardiac-stimulating properties. These characteristics make it a potential candidate for the development of drugs targeting conditions related to the uterus, bronchial spasms, and heart function.
Used in Organic Synthesis:
6,8-Dibromoimidazo[1,2-a]pyrazine serves as an intermediate in organic syntheses. Its unique chemical structure allows it to be a valuable building block for the creation of more complex molecules and compounds, contributing to the advancement of chemical research and development.

InChI:InChI=1/C6H3Br2N3/c7-4-3-11-2-1-9-6(11)5(8)10-4/h1-3H

Upstream product

• 107-20-0 2-chloroethanal 
• 24241-18-7 2-amino-3,5-dibromopyrazine 
• 17157-48-1 bromoacetaldehyde 
• 7252-83-7 1-bromo-2,2-dimethoxyethane 
• 2032-35-1 Bromoacetaldehyde diethyl acetal 

Downstream Products

• 117718-86-2 6-bromo-8-(ethylamino)imidazo<1,2-α>pyrazine 
• 886854-81-5 4-(6-bromo-imidazo[1,2-a]pyrazin-8-ylamino)-benzoic acid ethyl ester 
• 1021154-34-6 tert-butyl 4-(4-((6-bromoimidazo[1,2-a]pyrazin-8-yl)amino)phenyl)piperazine-1-carboxylate 
• 63744-24-1 3,6,8-tribromoimidazo[1,2-a]pyrazine 
• 746654-29-5 6-bromo-8-(4-p-tolyl-imidazol-1-yl)-imidazo[1,2-a]pyrazine 
• 445263-82-1 (6-bromo-imidazo[1,2-a]pyrazin-8-yl)-phenyl-amine 
• 1255097-90-5 C₁₇H₁₈BrN₅O 
• 445263-72-9 6-bromo-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazine-8-amine 
• 1255097-89-2 C₁₉H₁₄BrN₅O 
• 864546-06-5 4-(6-bromo-imidazo[1,2-a]pyrazin-8-ylamino)-cyclohexanol 
• 1255097-87-0 C₁₂H₈BrClN₄ 
• 1255097-86-9 C₁₃H₁₁BrN₄O 
• 1255097-88-1 C₁₄H₁₂BrN₅O 
• 1101322-35-3 4-Amino-2-[(2-{[6-(2,4-dichlorophenyl)imidazo[1,2-a]pyrazin-8-yl]amino}ethyl)amino]-1,3-thiazole-5-carbonitrile trifluoroacetate 

Relevant academic research and scientific papers

Synthesis of new triazole based imidazo[1,2-a]pyrazine-benzimidazole conjugates: H-bonding assisted FRET efficient ratiometric detection of pyrophosphate

Triazole tethered imidazo[1,2-a]pyrazine-benzimidazole conjugates 13-38 has been synthesized by click and Suzuki-Miyaura cross coupling reactions at C-8 and C-6 positions, respectively. The research findings clearly predicted that by modification of electronic structure of the receptor, the sensitivity of the recognition process could be modified. Compound 24 with hydroxyphenyl substituent, showed stronger binding to the pyrophosphate than other compounds. Compound 24 has been used as selective probe for ratiometric detection of pyrophosphate amongst the other anions. The binding event of compound 24 toward PPi has been successfully evaluated by absorption and emission spectroscopy as well as NMR titration method. The compound 24 showed H-bonding assisted facilitation of FRET phenomenon in the presence of PPi.

Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 4: Design, synthesis and biological evaluation of novel imidazo[1,2-a]pyrazines

Through a structure-guided core-refining approach, a series of novel imidazo[1,2-a]pyrazine derivatives were designed, synthesized and evaluated as HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs). Biological results of antiviral assay in MT

IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR

The present invention relates to the compound of formula (I) and salts, stereoisomers, tautomers, isotopologues,or N-oxides thereof. The present invention is further concerned with the use of such a compound or salt, stereoisomer, tautomer, isotopologues,or N-oxide thereof as medicament and a pharmaceutical composition comprising said compound.

Investigation of rotameric conformations of substituted imidazo-[1,2-a] pyrazine: Experimental and theoretical approaches

The different rotameric conformations of imidazo-[1,2-a]pyrazine have been synthesized and characterized by means of different experimental techniques, such as NMR, FTIR, and absorption spectroscopy and quantum chemical calculations. The different conformations were stabilized by hydrogen bonds, such as OH?N, ArH?N and ArH?ArH. The ground state optimizations and potential energy surface (PES) scanning profiles produced using density functional theory (DFT) show two stable rotameric forms for each molecule. The relative population of the conformations is affected by the strength of the hydrogen bonds. The calculated absorption spectra and isotopic shielding constants were acquired by time-dependent density functional theory (TD-DFT) and gauge invariant atomic orbitals (GIAO)-DFT, respectively. The strength of the hydrogen bonding interactions that resulted in the different conformations was studied by quantum theory of atoms in molecules (QTAIM).

Method for synthesizing 6,8-dibromo imidazo[1,2a] pyrazine

The invention relates to a method for synthesizing 6,8-dibromo imidazo[1,2a] pyrazine. The method comprises the following steps: by taking 2-amino-3,5-dibromo pyrazine and chloroacetaldehyde as raw materials, in a proper solvent, performing reaction for 4-12 hours at 25-150 DEG C, and purifying, thereby obtaining a purified product, namely, 6,8-dibromo imidazo[1,2a] pyrazine. According to the method, reaction raw materials are easily available, the material price is reasonable, the reaction condition is gentle, the operation is easy, the control is easy, the aftertreatment is simple, the product quality is stable and the purity is high.

IMIDAZOPYRAZINE DERIVED COMPOUNDS FOR ELECTRONIC DEVICES

The invention provides a composition comprising at least one compound of Formula 1 through Formula 8, each as described herein. These compounds, containing an imidazopyrazine moiety, are useful in organic electroluminescence devices.

FUSED PYRAZINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON TAK1

A compound selected from pyrazine fused-ring derivatives of a chemical formula 1 or pharmaceutically acceptable salts thereof has excellent inhibition activity with respect to TAK1 kinase. A pharmaceutical composition comprising the same is capable of increasing activity of anticancer drugs with respect to cancer or tumor by inhibiting activation of TAK1 kinase, with excellent effects as a prevention agent or a therapeutic agent of cancer or tumor. In the chemical formula 1, A, X, Y, W, Z, E, R^1, and m are the same as defined in the specification.COPYRIGHT KIPO 2016

Synthesis, in vitro anticancer activity and SAR studies of arylated imidazo[1,2-a]pyrazine-coumarin hybrids

A new series of imidazo[1,2-a]pyrazine-coumarin hybrids have been synthesized by the combination of two biologically active moieties, imidazo[1,2-a]pyrazine and coumarin, followed by the Suzuki-Miyaura cross coupling reaction for monoarylation at the C6 p

Structure-based drug design of RN486, a potent and selective Bruton's tyrosine kinase (BTK) inhibitor, for the treatment of rheumatoid arthritis

Structure-based drug design was used to guide the optimization of a series of selective BTK inhibitors as potential treatments for Rheumatoid arthritis. Highlights include the introduction of a benzyl alcohol group and a fluorine substitution, each of which resulted in over 10-fold increase in activity. Concurrent optimization of drug-like properties led to compound 1 (RN486) (J. Pharmacol. Exp. Ther. 2012, 341, 90), which was selected for advanced preclinical characterization based on its favorable properties.

COMBINATIONS FOR THE TREATMENT OF CANCER

The present invention relates to combinations of at least two compounds A and B, compound A being an inhibitor of Mps-1 kinase, and compound B being an inhibitor of an anti-apoptotic protein of the Bcl-2 family. Another aspect of the present invention relates to the use of such combinations as described supra for the preparation of a medicament for the treatment or prophylaxis of a disease, particularly for the treatment of cancer. Another aspect of the present invention relates to the use of an anti- apoptotic protein from the Bcl-2 family as a sensitizer of cells to Mps-1 inhibitors. Another aspect of the present invention relates to the use of the ratio of pro-apoptotic and anti-apoptotic proteins from the Bcl-2 family in a biological sample as a biomarker for a Mps-1 kinase inhibitor treatment.